Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Current Liabilities (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Total Current Liabilities data on record, last reported at $968.4 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 66.69% year-over-year to $968.4 million; the TTM value through Dec 2025 reached $968.4 million, up 66.69%, while the annual FY2025 figure was $968.4 million, 66.69% up from the prior year.
  • Total Current Liabilities reached $968.4 million in Q4 2025 per PTCT's latest filing, up from $866.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $968.4 million in Q4 2025 and bottomed at $250.9 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $541.7 million, with a median of $538.4 million recorded in 2021.
  • The widest YoY moves for Total Current Liabilities: up 95.0% in 2022, down 20.24% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $509.3 million in 2021, then dropped by 20.24% to $406.2 million in 2022, then surged by 48.46% to $603.1 million in 2023, then fell by 3.67% to $581.0 million in 2024, then skyrocketed by 66.69% to $968.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $968.4 million in Q4 2025, $866.2 million in Q3 2025, and $627.8 million in Q2 2025.